• About
    • About Sutro
    • Leadership
      • Leadership Team
      • Functional Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
    • Corporate Presentation
  • Clinical Trials & CUA
    • Clinical Trials
    • Patient Resources
    • Commitment To Patients
    • Compassionate Use Access
  • Technology
    • iADCs & Antibody-Drug Conjugates
    • XpressCF+®
    • cGMP Facility
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Pipeline
  • News
    • News Releases
    • Clinical / Scientific Presentation & Publication Highlights
    • Events
    • Events Audio Replays
  • Careers, Culture & DEIB
    • The Way We Work
    • Join Our Team
    • DEIB
      • DEIB Newsletter
    • Environmental Sustainability
    • Internships
    • Sutroites
    • Volunteer
      • Current Volunteer Newsletter
  • Contact Us

Sutro to Participate in the 30th Annual Piper Jaffray Healthcare Conference

Events

Sutro to Participate in the 30th Annual Piper Jaffray Healthcare Conference SOUTH SAN FRANCISCO, Calif., Nov. 26, 2018  — Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of...

Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer

Press Releases

Sutro Announces IND Submission and Conclusion of 30-Day Review Period for STRO-002, an Antibody-Drug Conjugate (ADC) Targeting Anti-Folate Receptor-α for Treatment of Ovarian and Endometrial Cancer Initiation of Phase 1 Trial Planned for Early 2019 Company’s Second...

Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors

News, Press Releases

Sutro Appoints Industry Veteran Shalini Sharp to Board of Directors Sharp to Bring Additional Financial Expertise to Sutro’s Board SOUTH SAN FRANCISCO, Calif., Nov. 8, 2018 — Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that Shalini Sharp, Chief...

Sutro’s STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma

Press Releases

Sutro’s STRO-001 Receives U.S. FDA Orphan Drug Designation for Treatment of Multiple Myeloma A New Generation of Precisely Engineered CD74-Targeting ADC SOUTH SAN FRANCISCO, Oct. 12, 2018– Sutro Biopharma, Inc. (NASDAQ: STRO),has been granted Orphan Drug...

Sutro Biopharma Announces $85.0 Million Initial Public Offering

Press Releases

Sutro Biopharma Announces $85.0 Million Initial Public Offering South San Francisco, California – September 26, 2018.  Sutro Biopharma, Inc., a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary integrated...
« Older Entries

Sutro Biopharma

310 Utah Ave
Suite 150
South San Francisco, CA 94080
650.392.8412

Sutro Biopharma

111 Oyster Point Blvd
South San Francisco, CA 94080
Phone: 650-881-6500
Fax: 650-553-9659

Google Map

Tweets by @sutrobio

Contact Us

General Inquires: general@sutrobio.com
Business Inquires: busdev@sutrobio.com
Investor Relations Inquires: IR@sutrobio.com
Careers:
jobs@sutrobio.com

Copyright © 2022 Sutro Biopharma, Inc. South San Francisco, California, U.S.A.
Privacy Policy
  • Follow
  • Follow
  • Follow
Sign Up for Email Alerts